Conveners
Session 10: Applied Nuclear Physics
- Patrick Regan (University of Surrey & The National Physical Laboratory, UK)
Alpha emitting radionuclides with medically relevant half-lives are interesting for treatment of tumors and other diseases because they deposit large amounts of energy close to the location of the radioisotope. Researchers at the Cyclotron Institute at Texas A&M University are developing a program to produce $^{211}$At, an alpha emitter with a 7.2 h half-life. The properties of $^{211}$At make...
The radiosensitivity of haematopoietic stem and progenitor cells (HSPCs) to neutron radiation remains largely underexplored, notwithstanding their role as target cells for radiation-induced leukemogenesis. This is important for radiation protection purposes, particularly for aviation, space missions, nuclear accidents and even particle therapy. In this study, HSPCs (CD34+ cells) were isolated...
Coupling alpha-emitting radionuclides with disease seeking targeting vectors for site-selective delivery of cytotoxic radiation has the potential to be a powerful technique for treating metastatic and hard to treat cancers. The success of this type of treatment, termed targeted alpha therapy (TAT), is reliant on the availability of isotope and ability to securely tether said isotope to a...
